However, our study clearly demonstrated that the primary tumor site (left- or right-sided) is a useful biomarker for predicting the prognosis after cetuximab treatment in patients with advanced KRAS wild-type (exon 2 nonmutant) CRC. The gene discussed is KRAS; the disease is neoplasm.